US FDA issues Form 483 to Gland Pharma

Following a pre-market inspection of Gland Pharma's Pashamylaram plant in Hyderabad, the U.S. FDA issued a Form 483 to the generic injectables manufacturer with two observations.

 

The Office of Medical Device and Radiological Health Operations, U.S. FDA, conducted the inspection covering the quality system/current good manufacturing practice rules for medical devices (21 CFR Part 820), from August 23 to 26. Regarding the ANDA filed for the product to be produced in a PEN device at the abovementioned facility, the company has received two observations on Form 483. Gland Pharma stated in a filing on Saturday that there has been no data integrity observation.

 

It stated that the company is dedicated to addressing the observations and would provide the U.S. FDA with a response within the allotted period.

 

Source: Media Reports

Related Blogs
blog-logo

Share Market

blog-logo

8 mins read . 19 Jul 2024

Stock Market Trading Time in India

  • 43 people read
blog-logo

Share Market

blog-logo

11 mins read . 19 Jul 2024

How To Trade in T2T Stocks

  • 43 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions